Participated · Series B · Jul 2026

Crystalys is advancing dotinurad, a next-generation, once-daily oral URAT1 inhibitor positioned as a second-line therapy to reduce uric acid, gout flares and tophi. Dotinurad was invented by Fuji Yakuhin and has regulatory approvals in Japan, China, the Philippines, Taiwan and Thailand, with supporting clinical data from those markets. The company is conducting the JEWEL clinical research program, which includes the Phase 3 RUBY and TOPAZ trials and the Phase 2 AMETHYST study to evaluate safety and efficacy across a broad spectrum of gout patients. Crystalys aims to position dotinurad as a best-in-class option for safety and efficacy and is preparing for global commercialization. The company is headquartered in San Diego and was co-founded by Catalys Pacific and Novo Holdings. With the announced $130 million Series B, Crystalys has increased its financial runway to support late-stage development and commercial readiness.

Participated · Series D · Jul 2026

FORE Biotherapeutics is a registration-stage targeted oncology company whose lead asset is plixorafenib (FORE8394; formerly PLX8394), a BRAF inhibitor with a mechanism described as both a dimer and paradox breaker. The company is advancing plixorafenib in the global Phase 2 FORTE Master Protocol, a registration-intended basket study that includes monotherapy baskets for recurrent or progressive BRAF V600E primary CNS tumors, rare BRAF V600 mutated solid tumors, and advanced solid tumors with BRAF fusions. Fore reported that target enrollment of approximately 50 patients has been reached in the BRAF V600E CNS tumor basket and expects topline results from that basket around the end of 2026; the company anticipates a potential regulatory submission if the primary analysis is positive. Plixorafenib received Breakthrough Therapy Designation from the FDA in April 2026, and prior Phase 1/2 data showed a 67% ORR in MAPK inhibitor–naïve BRAF V600 primary recurrent CNS tumors (n=9) and a 42% response rate with a median duration of response of 17.8 months in V600-altered, MAPK inhibitor–naïve patients. The company reported a favorable safety profile for plixorafenib, including a drug-related discontinuation rate of less than 2%, and has implemented protocol changes in FORTE such as allowing dosing with food and lowering the minimum enrollment age to 8 years based on IDMC clearance.

Participated · Series D · Jun 2026

Lycia Therapeutics is a California-based biotech company whose lead programs target disease-driving proteins that circulate in the blood. The company employs a platform the investor describes as able to reach proteins outside the cell, addressing targets conventional drugs cannot. Lycia has progressed through multiple financing rounds, with RTW Biotech participating in its Series B (September 2021), Series C (2024), and the current Series D. The recent Series D financing totals $75M, from which RTW invested $1.4M. Investors and coverage in the reporting frame the use of proceeds around advancing the pipeline toward clinical proof of concept. Financial metrics such as revenue or user counts were not disclosed in the article.

Participated · Series D · May 2026

CellCentric is a privately held, clinical-stage biotech company developing inobrodib, an orally bioavailable p300/CBP inhibitor. The lead program is in registration-enabling clinical trials for patients with relapsed/refractory multiple myeloma, and the company is enrolling a Phase 2 DOMMINO-1 study in the UK and US. CellCentric plans to initiate the global Phase 3 DOMMINO-2 trial in the second half of 2026. The company holds an IP portfolio and has clinical collaborations and strategic partnerships that provide external validation. Led by CEO Will West, CellCentric is based in Cambridge, UK, and maintains an additional office in Boston, MA. The article did not disclose revenue or other operating metrics.

Participated · Series D · Jan 2026

Founded in 2019 and led by CEO Sandy Mou, Corxel Pharmaceuticals (formerly JiXing Pharmaceuticals) focuses on discovering, developing, and commercializing therapies for cardiometabolic conditions. Its lead candidate, CX11, is in an ongoing U.S. Phase 2 trial for obesity and overweight patients and is scheduled for a global Phase 2 study targeting Type 2 Diabetes Mellitus, with Phase 3 preparations already underway. Beyond CX11, the company’s pipeline spans assets for hypertension, acute ischemic stroke, and ophthalmologic indications such as dry eye and presbyopia. Proceeds from its recent financing will also support advancement of these additional programs and expand global operational capabilities needed for multiregional clinical trials. The company operates from offices in Berkeley Heights, New Jersey, and China. As a clinical-stage firm, Corxel has not disclosed commercial revenues, but the latest capital infusion provides significant runway to progress multiple candidates through late-stage development.